Media Coverage

Sabinsa Selects Eurofins Scientific - happi.com

Will adopt proprietary methods to test Sabinsa ingredients

Sabinsa Corporation has selected Eurofins Scientific, an international leader in analytical testing with specialties in probiotic and supplement raw material analysis, as its global partner for botanical raw material ID testing as well as testing on Sabinsa’s patented extracts and probiotic ingredients.

Identity testing of proprietary ingredients can get complicated when the testing lab does not know which test methods are best for a specific ingredient. When a testing lab uses different methods than the manufacturer, or even other labs, it can cause inaccurately “failed” test results. This wastes time, money, and sometimes even good will. In response to these market and contract manufacturer challenges in ingredient verification, Eurofins will adopt proprietary methods from Sabinsa to test the company’s ingredients.

“As you look at the supply chain, the need for 3rd party verification is increasing – but it becomes increasingly difficult analytically as new products come to market and test methods are not expanded in validation,” said Anurag Pande, VP Scientific Affairs, Sabinsa. “We believe it will simplify ID testing for our customers to have a lab available with this level of knowledge on testing our proprietary ingredients.”

Proprietary methods developed by Sabinsa’s parent company Sami Labs being shared with Eurofins includes LactoSpore® enumeration along with extracts such as Curcumin C3 Complex®, BioPerine®, ForsLean® and many more, to support contract manufacturers and marketing companies looking for validation.

Sabinsa Corporation with its state of art analytical lab in India has developed several in-house analytical methods for assay of active components in herbal products. These methods have been validated using ICH guidelines for all major parameters including specificity, precision and accuracy.


Sami-Sabinsa, Eurofins sign agreement for Proprietary Ingredients - Nuffoods Spectrum

Sami-Sabinsa Group has elected the analytical testing services company Eurofins Scientific, an international leader in analytical testing with specialties in probiotic and supplement raw material analysis, as their global partner for botanical raw material ID testing as well as testing on Sabinsa’s patented extracts and probiotic ingredients.

Identity testing of proprietary ingredients can get complicated when the testing lab does not know which test methods are best for a specific ingredient. When a testing lab uses different methods than the manufacturer, or even other labs, it can cause inaccurately “failed” test results. This wastes time, money, and sometimes even good will. In response to these market and contract manufacturer challenges in ingredient verification, Eurofins will adopt proprietary methods from Sami-Sabinsa to test the company’s ingredients.

“As you look at the supply chain, the need for 3rd party verification is increasing – but it becomes increasingly difficult analytically as new products come to market and test methods are not expanded in validation,” said Anurag Pande, VP Scientific Affairs, Sabinsa. “We believe it will simplify ID testing for our customers to have a lab available with this level of knowledge on testing our proprietary ingredients.”

Proprietary methods developed by Sabinsa’s parent company Sami Labs being shared with Eurofins includes LactoSpore enumeration along with extracts such as Curcumin C3 Complex, BioPerine, ForsLean and many more, to support contract manufacturers and marketing companies looking for validation.

Sami-Sabinsa Group with its state of art analytical lab in India has developed several in-house analytical methods for assay of active components in herbal products. These methods have been validated using ICH guidelines for all major parameters including specificity, precision and accuracy.


Sabinsa Picks Eurofins Global Partner for ID Testing of Proprietary Ingredients - WholeFoodsMagazine

Sabinsa Corporation announced that they have chosen Eurofins Scientific for use of their analytical testing services, making them their global partner for botanical raw material ID testing.

Eurofins specializes in the analytical testing of probiotics and supplement raw materials and will adopt proprietary methods of testing from Sabinsa for testing the company’s ingredients. This is because inconsistency in the testing methods of proprietary ingredients between the testing lab and the manufacturer can create inaccurately failed test results. The methods developed by Sami Labs, Sabinsa’s parent company that are being shared include LactoSpore enumerations in addition to Curcumin C3 Complex, Bioperine and ForsLean.

“As you look at the supply chain, the need for 3rd party verification is increasing — but it becomes increasingly difficult analytically as new products come to market and test methods are not expanded in validation,” said Anurag Pande, VP Scientific Affairs, Sabinsa. “We believe it will simplify ID testing for our customers to have a lab available with this level of knowledge on testing our proprietary ingredients.”


Sami-Sabinsa & Eurofins enter into global ID testing agreement for proprietary ingredients - BioVoice

Proprietary methods developed by Sabinsa’s parent company Sami Labs and being shared with Eurofins include LactoSpore enumeration along with extracts such as Curcumin C3 Complex, BioPerine, ForsLean and many more.

Sami-Sabinsa Group has selected the analytical testing services company Eurofins Scientific, an international leader in analytical testing with specialties in probiotic and supplement raw material analysis, as their global partner for botanical raw material ID testing as well as testing on Sabinsa’s patented extracts and probiotic ingredients.

Identity testing of proprietary ingredients can get complicated when the testing lab does not know which test methods are best for a specific ingredient. When a testing lab uses different methods than the manufacturer, or even other labs, it can cause inaccurately “failed” test results. This wastes time, money, and sometimes even good will. In response to these market and contract manufacturer challenges in ingredient verification, Eurofins will adopt proprietary methods from Sami-Sabinsa to test the company’s ingredients.

“As you look at the supply chain, the need for 3rd party verification is increasing – but it becomes increasingly difficult analytically as new products come to market and test methods are not expanded invalidation,” said Anurag Pande, VP Scientific Affairs, Sabinsa. “We believe it will simplify ID testing for our customers to have a lab available with this level of knowledge on testing our proprietary ingredients.”

Proprietary methods developed by Sabinsa’s parent company Sami Labs being shared with Eurofins includes LactoSpore enumeration along with extracts such as Curcumin C3 Complex, BioPerine, ForsLean and many more, to support contract manufacturers and marketing companies looking for validation.

Sami-Sabinsa Group with its state of art analytical lab in India has developed several in-house analytical methods for assay of active components in herbal products. These methods have been validated using ICH guidelines for all major parameters including specificity, precision and accuracy.

 

    VISIT US

  • Edifício Koerich Beiramar Office
    Avenida Mauro Ramos
    1970- Sala 705-Centro
    Florianópolis-SC
    Brasil CEP 88.020-302

  • +55 48 3206 3682
  • info@sabinsa.com.br

CERTIFICATES

Certificate Logos Certificate Logos
Certificate Logos Certificate Logos

CONTACT US

Disclaimer

Please note that this website and information provided herein is not for final consumers of a finished food, beverage, dietary supplement product or cosmetic product, as the information contained herein does not refer to finished products for consumers.

The information provided on the website is intended only for producers of finished food, beverage, dietary supplement and cosmetic product.

The statements related to ingredients on the website, have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.

The website and information herein are available in various countries across the world, and hence statements or product information including its classification may not be applicable in your country.

Information and statements provided on the website, shall not be construed as license to practice, or recommendations to infringe, any patents or other intellectual property rights of Sabinsa and others.

By browsing further, You understand the above terms.